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Abstract
Background: Despite increasing recognition of the importance of involving patients in decisions
on preventive healthcare interventions, little is known about how well patients understand and
utilise information provided on the relative benefits from these interventions. The aim of this study
was to explore whether lay people can discriminate between preventive interventions when
effectiveness is presented in terms of relative risk reduction (RRR), and whether such
discrimination is influenced by presentation of baseline risk.
Methods: The study was a randomised cross-sectional interview survey of a representative sample
(n = 1,519) of lay people with mean age 59 (range 40–98) years in Denmark. In addition to
demographic information, respondents were asked to consider a hypothetical drug treatment to
prevent heart attack. Its effectiveness was randomly presented as RRR of 10, 20, 30, 40, 50 or 60
percent, and half of the respondents were presented with quantitative information on the baseline
risk of heart attack. The respondents had also been asked whether they were diagnosed with
hypercholesterolemia or had experienced a heart attack.
Results: In total, 873 (58%) of the respondents consented to the hypothetical treatment. While
49% accepted the treatment when RRR = 10%, the acceptance rate was 58–60% for RRR>10.
There was no significant difference in acceptance rates across respondents irrespective of whether
they had been presented with quantitative information on baseline risk or not.
Conclusion: In this study, lay people's decisions about therapy were only slightly influenced by the
magnitude of the effect when it was presented in terms of RRR. The results may indicate that lay
people have difficulties in discriminating between levels of effectiveness when they are presented
in terms of RRR.
Background
Patient autonomy is a core element of medical ethics.
Patient autonomy implies that patients and doctors share
responsibility for medical decision to the extent patients
wish to be included. For shared decision making to be
meaningful, however, patients need to have an under-
Published: 17 July 2008
BMC Medical Informatics and Decision Making 2008, 8:31 doi:10.1186/1472-6947-8-31
Received: 7 February 2007
Accepted: 17 July 2008
This article is available from: http://www.biomedcentral.com/1472-6947/8/31
© 2008 Sorensen et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Medical Informatics and Decision Making 2008, 8:31 http://www.biomedcentral.com/1472-6947/8/31
Page 2 of 7
(page number not for citation purposes)
standing of the effectiveness of medical interventions.
This usually requires the use of the risk concept. Commu-
nicating risk information is therefore a fundamental and
increasingly prominent part of medical practice. Effective
risk communication can enhance knowledge, involve-
ment in decisions about testing or treatment, autonomy
and empowerment of patients [1]. However poor com-
munication may possibly lead to anxiety or lack of confi-
dence in health care professionals [2]. It is vital that we
identify the available evidence about how risk communi-
cation should best be done.
The effectiveness of an intervention for a chronic disease
may be presented in terms of Relative Risk Reduction
(RRR), Absolute Risk Reduction (ARR), Numbers Needed
to Treat (NNT), or Odds Ratio (OR). These measures may
subsequently be translated into increased (disease-free)
life expectancy because the intervention postpones
adverse events. The choice of effect measure has been dis-
cussed extensively in the scientific literature (e.g. by Gig-
erenzer et al [3] or Elmore et al [4]), but we still need more
knowledge about how intervention effectiveness can be
communicated to patients, doctors and health adminis-
trators.
Decisions should, in line with expected utility theory [5],
be based on the absolute risk reductions (or its reciprocal
NNT) even though this principle in practice is frequently
violated. However, there is evidence that lay-persons and
professionals may have difficulties in understanding NNT
[6-8]. Great effectiveness of a treatment corresponds with
low value of NNT, and this may mislead patients if they
associate great effectiveness with a large number. In con-
trast, for RRR a greater value means greater effectiveness.
RRR, however, may be misleading because it usually is
greater than ARR numerically, and may consequently
"exaggerate" the treatment effect. Still, RRR is frequently
presented in the medical literature, possibly because it is
more stable across patient groups than ARR [9]. It is there-
fore conceivable that doctors on some occasions use RRR
in their communication with patients. Even though deci-
sions should not be based on RRR alone, we need to know
to which extent patients can utilise information about
RRR. We have searched the literature without finding any
direct evidence of the extent to which lay people under-
stand RRR.
The size of baseline risk has been shown to influence
acceptance of a hypothetical treatment [8]. Usually, base-
line risk is presented to supplement RRR to allow for cal-
culation of ARR. In the current study, we tested whether
presence or absence of baseline risk information, pro-
vided in addition to RRR information, affects acceptance
of a hypothetical treatment. In theory, absence of baseline
risk leaves the respondent without sufficient information
to properly decide on whether or not to accept a treat-
ment, because ARR cannot be derived. Real life decisions
are, nevertheless often made without sufficient informa-
tion [10,11].
We hypothesised that respondents are sensitive to the
magnitude of RRR in decisions about a preventive ther-
apy, i.e. respondents are able to differentiate between low
and high levels of RRR. We also hypothesised that
numeric presentation of baseline risk will reduce respond-
ents' general acceptance of the hypothetical treatment for
all levels of RRR, because the presentation of this added
piece of information allows the respondent to assess the
absolute effect of the intervention. The aim of this study
was to test these hypotheses in a sample of laypersons.
Methods
A random sample of non-institutionalised Danes aged
40+ years was interviewed face-to-face through computer-
assisted personal interviews by Gallup Inc, Denmark.
Questions were concurrently presented to the respond-
ents orally and in writing on cards.
A sample of 3,548 individuals aged 40+ years was ran-
domly drawn from a national database at Statistics Den-
mark. The sampling ensured geographic representativity.
A total of 415 individuals could not be contacted because
they were either non fluent in Danish (n = 62), suffered
from sickness, senile dementia or reduced hearing (n =
154) or because the address identified was non-inhabited,
non-existing or used for industrial purposes (n = 199)).
The net sample consisted of 3,133 individuals. After three
attempts, 731 potential respondents could still not be
contacted, and 883 refused participation. All together
1,519 (49%) respondents completed an interview.
Information on age, gender, marital status, education and
household income was collected. The two latter variables
were included, because it is conceivable that understand-
ing of risk information is higher in population groups
with higher income or education. Respondents were also
asked whether they were diagnosed with hypercholestero-
laemia or had experienced a heart attack.
Additionally, the respondents were asked to consider a
hypothetical intervention (see below). Similar questions
have been used in previous studies conducted by Odense
Risk Group, wherefore no pilot testing was performed. In
order to test whether baseline risk had an effect on the
acceptance of this intervention presented in terms of RRR,
respondents were allocated to alternative versions of a
case scenario in which baseline numeric risk information
was either present or not. The following wording was
used:BMC Medical Informatics and Decision Making 2008, 8:31 http://www.biomedcentral.com/1472-6947/8/31
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￿ Version 1:"Imagine that your GP tells you that you have
a slightly increased risk of suffering a heart attack. On
average, 10 out of 1000 patients like you will die of a heart
attack within 3 years."
￿ Version 2:"Imagine that your GP tells you that you have
a slightly increased risk of suffering a heart attack."
Subsequently, the following information was given to all
respondents:
Your GP presents you with a medication, which
should be taken once a day. The medication has mild
and harmless side effects. The treatment requires that
you visit your GP twice a year for a check-up. The
annual cost of your medication is approximately 500
DKK (~£45), which you will have to pay yourself.
Your GP tells you that the use of the medication for 3 years
will reduce your risk of heart attack by X%."
The impact on choice of the magnitude of RRR was tested
by randomly allocating respondents to varying X = 10, 20,
30, 40, 50, 60. We chose these levels because most medi-
cal interventions attain effectiveness within this range.
RRR was presented as percentages because this is the way
they are usually presented in the medical literature even
though relative frequencies may be easier to understand
[3]. By random, half of the respondents in each RRR group
were presented with the baseline risk of heart attack, while
the others were not. The randomisation was done by a
computer at the start of the interview.
Subsequently, the respondents were asked whether they
would choose to take the medication, and also asked to
answer a question regarding their perceived difficulty of
understanding the RRR information. The following preset
answer categories were presented:
"Was it difficult to understand the size of the treatment
effect?"
￿ Not difficult to understand
￿ A little difficult to understand
￿ Very difficult to understand
￿ Impossible to understand
In the subsequent analyses, the responses were recoded
into a dichotomous variable, where one category repre-
sented those who had no difficulties understanding the
case, and the other category represented the remaining
respondents.
Variation in consent with increasing RRR was tested with
bivariate trend analysis. Additionally, logistic regression
was performed to explore determinants of consent includ-
ing presentation of baseline risk.
With 125 respondents in each RRR-group, we had a power
of 99% to detect a trend describing an increase from 40%
to 75% acceptance of therapy with increasing effective-
ness. A similar effect has been observed in a study of pro-
longation of life as measure of benefit [12].
Results
The mean age of the 1,519 respondents was 59.6 years,
and 53.9% were women. Age, gender and geographic
location of the respondents were similar to that of the
background population in Denmark, according to Gallup
Inc, who performed the selection of the respondents. Pre-
vious heart attack was reported by 6% of the respondents,
and 19% reported hypercholesterolaemia, and both val-
ues were similar to measures found in the background
population. After randomising respondents into the dif-
ferent RRR information groups, no differences were found
between the groups with regard to age, household
income, gender and prevalence of hypercholesterolaemia
or previous heart attack (Table 1).
On average 58% of respondents accepted the hypothetical
drug treatment, 27% rejected it and 15% were uncertain
(Table 2). There was a significant trend towards increasing
acceptance to the treatment with increasing RRR for
respondents presented with baseline risk (χ2-test for
trend, p = 0.02), but the trend was not sustained when
RRR = 10 was excluded from the analysis (χ2-test for trend,
p = 0.11). No significant trend was found for respondents
who were not presented with baseline risk, even when
RRR was included. (p  = 0.45) (Table 2). Presence or
absence of baseline risk did not influence the respond-
ents' general willingness to accept the treatment (Table 2).
Among the respondents, 76% reported that it was not dif-
ficult to understand RRR, while 17% found it somewhat
difficult, 4.5% very difficult and 2.4% found it impossible
to understand. There was no difference in reported under-
standing of RRR across respondents presented or not pre-
sented with baseline risk information (24.2% versus
24.0%, p = 0.92). Respondents, who reported no difficul-
ties understanding the concept, were more likely to accept
the hypothetical treatment irrespective of RRR-level and
whether baseline risk had been presented.
Low income was associated with high prevalence of self-
reported hypercholesterolaemia, high self-reported previ-
ous heart attack, and difficulties with understanding the
RRR concept (all χ2 trend analyses p < 0.001).BMC Medical Informatics and Decision Making 2008, 8:31 http://www.biomedcentral.com/1472-6947/8/31
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According to a logistic regression analysis (Table 3),
respondents presented with a RRR of 10 were less likely to
accept the treatment when using RRR = 60 as reference,
while there was no difference for the other groups. Those
diagnosed with hypercholesterolaemia or heart disease
were more likely to accept the hypothetical treatment, as
were respondents who did not find it difficult to under-
stand RRR. Further, the odds for accepting the hypotheti-
cal treatment increased with higher household incomes,
but decreased with higher levels of education.
With the purpose of possibly confirming higher sensitivity
to RRR when baseline risk was presented in numeric terms
(as indicated by the trend analysis, Table 2), logistic
regression was performed including an additional interac-
tion variable: RRR*baseline risk. This interaction variable
was not significant in the logistic regression, and an effect
of baseline risk on effect of RRR information could not be
confirmed.
Discussion
It is conceivable that effectiveness, along with costs and
side effects, is a core issue when people consider a poten-
tial therapy. We therefore expected the consent to the
hypothetical therapy to increase with increasing effective-
ness. The results of the study, however, indicate only weak
and inconsistent effects. In theory, information on base-
line risk is necessary to interpret RRR correctly, but such
information had only little impact on the choices
respondents made in this study. Hence, in a hypothetical
situation, respondents are only slightly influenced by a
difference between 10% versus 60% RRR of the given drug
treatment, and RRR-effect was not influenced by presenta-
tion of baseline risk.
Presentation of baseline risk did not affect respondents'
general acceptance of the hypothetical treatment accord-
ing to the logistic regression analysis (Table 3). This was
in contrast to our expectations that fewer respondents
would accept the treatment when presented with baseline
risk, because presentation of baseline risk makes the small
absolute benefit more evident. These results do however
accord with previous evidence of baseline neglect [10,11].
A specific problem associated with our design is also that
one could argue that base-line risk was – in some form –
presented to all respondents, and it is conceivable that 1%
baseline risk is perceived as about the same risk as
"slightly increased risk of heart attack". I.e. an explanation
could be that baseline risk was fairly low. Another expla-
Table 1: Characteristics of respondents in each group
RRR = 10 RRR = 20 RRR = 30 RRR = 40 RRR = 50 RRR = 60 All
Age (years): mean median 
(minimum-maximum)
59.5 58.0 
(40–93)
59.0 58.0 
(40–90)
59.6 58.0 
(40–91)
60.3 58.0 
(40–98)
59.7 57.0 
(40–90)
59.7 58.5 
(40–92)
59.6 58.0 
(40–98)
Household income, 1,000 
DKK*: median**
300–399 300–399 200–299 300–399 300–399 300–399 300–399
Proportion female 49.6% 56.5% 56.9% 50.4% 55.1% 55.0% 53.9%
Prevalence of 
hypercholesterolaemia
16.8% 22.3% 19.1% 19.2% 17.0% 16.6% 18.6%
Prevalence of previous heart 
attack
5.6% 7.8% 3.4% 7.1% 5.6% 7.1% 6.0%
*£1.00 = DKK11, **(minimum = (<DKK100,000, maximum- = DKK799,000+)
Table 2: Preferences for heart attack prevention according to its effectiveness in terms of RRR
"Would you choose to take such a drug?"
Baseline risk presented Baseline risk not presented
RRR Yes (%) No (%) Uncertain (%) RRR Yes (%) No (%) Uncertain (%)
10 (n = 128) 50.0 37.5 12.5 10 (n = 126) 47.6 34.9 17.5
20 (n = 152) 55.9 28.3 15.8 20 (n = 110) 65.5 20.0 14.5
30 (n = 130) 53.8 33.1 13.1 30 (n = 139) 61.9 20.1 18.0
40 (n = 139) 58.3 25.9 15.8 40 (n = 117) 57.3 26.5 16.2
50 (n = 130) 60.0 25.4 14.6 50 (n = 106) 60.4 29.2 10.4
60 (n = 127) 63.8 22.8 13.4 60 (n = 115) 56.5 20.9 22.6
Total (n = 806) 56.9 28.8 14.3 Total (n = 713) 58.1 25.2 16.7BMC Medical Informatics and Decision Making 2008, 8:31 http://www.biomedcentral.com/1472-6947/8/31
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nation may simply be lack of numeracy skills among
some respondents.
Gyrd-Hansen et al [8] explored whether presentation of
baseline risk had an effect on treatment choices and found
that lower baseline risk and thus higher RRRs (holding
ARR constant) resulted in greater acceptance rates. The
current study could not extend this previous finding to a
more general effect of the presence of baseline risk infor-
mation. This may be due to a different study design, where
we test for the effect of presence/absence of baseline risk
information rather than varying baseline risk. Alterna-
tively, the reason may be that the cognitive burden of cal-
culating ARR on the basis of RRR and baseline risk is
greater than that of calculating RRR on the basis of ARR
and baseline risk. The ideal design would involve many
levels of both RRR and baseline risk. This would inflate
the necessary number of respondents, a design that was
not feasible in the present study.
We found a positive relationship between self-reported
understanding of the RRR concept and acceptance of the
treatment, which suggests that respondents, who think
they understand the concept, are more likely to opt for the
treatment. There was no association, however, between
self-reported understanding of RRR and presentation of
baseline risk. This suggests that respondents' perceived
understanding does not depend on whether they have
received sufficient information to make a fully informed
decision. This result is important when communicating
the effect of a medical treatment, since those who say that
they understand the concept off RRR do not necessarily
understand that they need baseline risk to use RRR prop-
erly.
In several studies [6,13-18], respondents have been more
likely to accept an intervention when its effectiveness was
presented in terms of RRR rather than NNT. In the afore-
mentioned study by Kristiansen et al [7], the acceptance
rate was on average 80% for NNT while it was only 60%
in the present study of RRR with a similar design. In both
studies, the price of the drug, the side effects and the need
for medical follow-up were quite similar. When our study
and the study by Kristiansen [7] seemingly contradict pre-
vious findings [6,13-18], the explanation may be found in
small differences in the format of the two studies. Lay peo-
ple may be quite sensitive to small differences in presen-
tation of disease, side effects, and price while they may be
insensitive to considerable differences in treatment effec-
tiveness.
In another study with similar design [19], respondents'
preferences for a therapy were strongly influenced by
treatment effectiveness expressed as postponement of hip
fracture. The question is then why preferences for therapy
were little influenced in this study off RRR. The explana-
tion is probably that laypeople, who are not familiar with
relative risks, are almost unable to get meaningful infor-
mation out of the numbers even if they understand the
numbers themselves. In the absence of real understanding
of effectiveness, people will tend to use other information,
which they do understand. Such pieces of information
may be type of disease (for example osteoporosis versus
hypercholesterolaemia), type of outcome (heart attack
versus death), costs etc as found in a study concerning
NNT [6].
Finally, the significant effect of income on acceptance of
the treatment suggests that respondents may have consid-
ered and applied the cost information when responding.
The respondents appear to have understood and consid-
Table 3: Multiple logistic regression analysis of the odds for accepting the hypothetical treatment (0 = no or uncertain, 1 = yes)
Variable Odds ratio (95% CI)
Baseline risk presented (0 = no, 1 = yes) 1.14 0.90–1.44
RRR (reference: RRR = 60)
RRR = 10 0.60* 0.39–0.90
RRR = 20 1.03 0.69–1.55
RRR = 30 0.91 0.60–1.38
RRR = 40 0.97 0.64–1.46
RRR = 50 1.05 0.69–1.59
Level of education (1–8; 1 = lowest, 8 = highest) 0.93* 0.87–0.99
Annual household income (1–8; 1 = <DKK 100,000, 8 = DKK 799,000+) 1.09* 1.01–1.17
Suffer from hypercholesterolaemia (0 = no, 1 = yes) 1.78* 1.27–2.49
Previously experienced heart attack (0 = no, 1 = yes) 2.38* 1.27–4.47
Respondents finding RRR difficult to understand (0 = no, 1 = yes) 0.33* 0.25–0.44
N = 1245, Respondents excluded from the analysis due to missing data; 274 (15.4%). -2log likelihood = 1585.577, χ2 = 102.344, p < 0.001.
*: p < 0.05BMC Medical Informatics and Decision Making 2008, 8:31 http://www.biomedcentral.com/1472-6947/8/31
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ered some of the information presented to them, while
remaining insensitive to the risk information. However, it
is also possible that other factors may be related to
income, e.g. education or health literacy, which may affect
respondents to trust the medical system or be more will-
ing to take medications. This observation emphasises the
problems associated with communicating this type of
information to lay people.
Limitations
Some of the findings were unexpected, but they should,
however, be seen against the limitations of the study. It is
likely that a discrepancy exists between a choice made in
a hypothetical situation and a choice made in a real life
situation. A similar problem exists when comparing the
agreement of doctors' responses to written simulations
compared to their responses to actual clinical encounters
[20], and the validity of hypothetical scenarios is not
established. More research is needed to decide whether
theoretical situations can measure actual behaviour. Ide-
ally, the study should have been undertaken among real
patients, but earlier studies on NNT would not indicate
that patients are better able to handle risk information
than healthy lay persons [21].
The way we presented the RRR percentages to the respond-
ents is somewhat ambiguous in that the numbers
(10%–60%) may be interpreted as absolute risk reduc-
tions. We believe that this potential misunderstanding
was not a major problem in the study. First, 10% or more
ARR is reduction is unrealistic for most interventions
although respondents may not know this. Second, the
responses were about the same whether or not respond-
ents were presented with baseline risk. Those who were
informed about baseline risk would know that the
numeric information was relative, not absolute.
Further aspects of whether the respondents understood
the RRR concept could have been explored by e.g. making
a direct check asking the respondent to recall the exact
RRR percentage, and asked the respondents of their per-
ceived effectiveness of the drug.
Conclusion
In conclusion, respondents were in general insensitive to
RRR information whether baseline risk information was
presented or not. This finding is in line with previous
studies, which suggest that lay people have difficulties in
understanding risk information, but stands in contrast to
studies that show that lay people can differentiate
between level of effectiveness when it is presented in
terms of postponement of adverse events such as death or
hip fracture [21]. Informed and shared decision making
requires methods of communicating intervention effec-
tiveness that is well understood and applied by patients in
the decision making process. Information on risk reduc-
tion in absolute terms is necessary to make rational
choices, but relative risks may be frequently used in prac-
tice. This study represents an additional argument against
the use of RRR when informing patients about treatment
effectiveness.
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